Chemotherapy was discovered through a combination of wartime secrecy, laboratory accidents, and researchers following leads that turned out to be wrong in exactly the right way. The story begins during World War II, when scientists studying chemical weapons noticed that mustard gas destroyed white blood cells, and it stretches across decades of unexpected breakthroughs that collectively built modern cancer treatment.
Chemical Weapons and the First Injection
The origin of chemotherapy is rooted in poison gas. During World War I, soldiers exposed to mustard gas suffered severe damage to their bone marrow and lymph nodes, the very tissues where white blood cells are produced. Two pharmacologists at Yale, Alfred Gilman and Louis Goodman, recognized something in that destruction: if mustard gas could wipe out healthy white blood cells, a modified version might do the same to cancerous ones.
Working under wartime secrecy in the early 1940s, Gilman and Goodman developed nitrogen mustard, a chemical relative of the battlefield agent, and tested it on mice with lymphoma. The tumors shrank. They then arranged for the first human injection, treating a patient with advanced lymphosarcoma (a cancer of the lymph system) who had exhausted all other options. The tumors regressed noticeably, though they eventually returned. The results were so intertwined with the classified weapons program that the findings weren’t published until 1946, after the war ended. It was crude, it was temporary, but it was the first demonstration that a chemical compound could push back a human cancer.
A Children’s Doctor Bets on Vitamins
While nitrogen mustard worked against lymph cancers, childhood leukemia remained untouchable. In 1948, a Boston pathologist named Sidney Farber tried something radical. He knew that folic acid, a B vitamin, fueled the growth of white blood cells. He reasoned that blocking folic acid might starve leukemia cells, which are essentially white blood cells growing out of control. He obtained a compound called aminopterin, designed to interfere with the body’s use of folic acid, and gave it to children with acute leukemia.
Of the sixteen children treated, ten entered remission. Their blood and bone marrow cleared of cancer cells, their symptoms resolved, and their enlarged livers and spleens shrank back toward normal size. One child’s leukemic skin nodules disappeared entirely. The longest complete remission lasted 47 days. By today’s standards, that sounds heartbreakingly short. At the time, it was unprecedented. No drug had ever produced a remission in leukemia. Farber’s work established the principle that cancer could be treated by blocking a specific biological process the cancer cells depended on, a concept that still drives drug development today.
A Diabetes Study That Found Cancer Drugs
Some of the most important chemotherapy agents were discovered by researchers who weren’t looking for them. In the late 1950s, scientists in Canada were studying extracts from the Madagascar periwinkle plant because folk medicine traditions suggested it could treat diabetes. The extracts turned out to be useless for blood sugar. But lab animals receiving them showed a dramatic drop in white blood cell counts, which pointed toward potential cancer applications.
That accidental finding led to the isolation of two compounds, vinblastine and vincristine, which block cancer cells from dividing by disrupting the internal scaffolding cells need to pull apart during division. Both became staples of cancer treatment, effective against leukemias, lymphomas, and several solid tumors. The periwinkle story illustrates a recurring theme in chemotherapy’s history: researchers stumbled onto cancer treatments while investigating something entirely unrelated.
Platinum Electrodes and a Lucky Experiment
In 1965, a biophysicist named Barnett Rosenberg at Michigan State University was running electricity through platinum electrodes submerged in a solution of E. coli bacteria. He wanted to see whether electrical fields affected cell division. As soon as the current started, the bacteria stopped dividing but kept growing, ballooning to 300 times their normal length.
Rosenberg initially thought the electric field was responsible. After extensive troubleshooting, his team realized electricity had nothing to do with it. A platinum compound was leaching off the electrodes into the solution, and that compound was blocking cell division. The discovery led to cisplatin, which became one of the most widely used chemotherapy drugs in history. It transformed testicular cancer from a frequently fatal diagnosis into one with cure rates above 90 percent, and it remains a backbone of treatment for bladder, lung, and ovarian cancers.
Tree Bark From the Pacific Northwest
In 1962, a botanist with the U.S. Department of Agriculture named Arthur Barclay collected bark samples from the Pacific yew tree during a field trip in Washington State. The samples were part of a massive screening effort: between 1955 and 1967, the National Cancer Institute acquired and tested over 114,000 synthetic and natural products searching for anti-cancer activity. The yew bark extract showed promise, but understanding how it worked took nearly two more decades.
In 1979, Susan Band Horwitz at Albert Einstein College of Medicine figured out the mechanism. The compound, later named paclitaxel, killed cancer cells by preventing them from dividing, but through a pathway no existing drug used. While other anti-division drugs worked by preventing cellular scaffolding from assembling, paclitaxel did the opposite: it locked the scaffolding in place so rigidly that cells couldn’t complete division and died. That unique mechanism made it effective against cancers that had become resistant to other treatments. It went on to become a cornerstone therapy for breast and ovarian cancers.
Combining Drugs Changed Everything
For the first two decades of chemotherapy, doctors used one drug at a time. Single agents could shrink tumors, but cancers almost always came back because some cells were naturally resistant to any individual drug. The breakthrough came from a simple idea: hit the cancer with multiple drugs simultaneously, each attacking through a different mechanism, to reduce the odds that any cell could survive them all.
The proof arrived in the 1960s with a four-drug regimen for Hodgkin’s disease (a lymph cancer). The combination included nitrogen mustard, the descendant of the original wartime compound, alongside vincristine from the periwinkle plant, plus two other agents. Among 188 patients treated, 84 percent achieved complete remission, meaning no detectable cancer remained. Two-thirds of those patients stayed disease-free for more than ten years. Nearly half of all patients survived between 9 and 21 years from the end of treatment. Before combination therapy, advanced Hodgkin’s disease was considered incurable. This regimen turned it into one of the first cancers that chemotherapy could reliably cure.
Combination chemotherapy became the standard approach for nearly all cancers treated with drugs, and the principle of attacking cancer through multiple pathways at once still guides treatment design today.
From Poisons to Precision
What’s striking about chemotherapy’s discovery is how many of its foundational drugs came from accidents, failed experiments, and repurposed poisons. Mustard gas, a weapon designed to kill soldiers, led to the first cancer drug. A failed diabetes remedy produced two of oncology’s most important plant-derived agents. An unrelated physics experiment yielded cisplatin. A government botanist’s routine bark collection produced paclitaxel.
The National Cancer Institute’s early screening program formalized this process. By the late 1950s, the program had tested around 11,000 compounds and was recognized for pushing new methods of identifying anti-cancer activity. That systematic effort, combined with the serendipitous discoveries happening in labs around the world, built the foundation of modern oncology. Each accidental finding revealed a new vulnerability in how cancer cells grow and divide, and each became a tool that doctors could combine, refine, and deploy against a disease that had previously been treated only with surgery and radiation.